IN8bio, Inc.
INAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $2,501 | $0 | $0 |
| Gross Profit | $0 | -$2,501 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $16,962 | $16,827 | $14,062 | $7,347 |
| G&A Expenses | $12,637 | $13,510 | $14,459 | $7,306 |
| SG&A Expenses | $12,637 | $13,510 | $14,459 | $7,306 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $838 | -$2,501 | $0 | $0 |
| Operating Expenses | $30,437 | $27,836 | $28,521 | $14,653 |
| Operating Income | -$30,437 | -$30,337 | -$28,521 | -$14,653 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $330 | $0 | $0 |
| Pre-Tax Income | -$30,437 | -$30,007 | -$28,521 | -$14,653 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$30,437 | -$30,007 | -$28,521 | -$14,653 |
| % Margin | – | – | – | – |
| EPS | -0.57 | -1 | -1.36 | -0.78 |
| % Growth | 43% | 26.5% | -74.4% | – |
| EPS Diluted | -0.57 | -1 | -1.36 | -0.78 |
| Weighted Avg Shares Out | 53,547 | 29,865 | 20,968 | 18,781 |
| Weighted Avg Shares Out Dil | 53,547 | 29,865 | 20,968 | 18,781 |
| Supplemental Information | – | – | – | – |
| Interest Income | $230 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2,655 | $2,501 | $1,103 | $788 |
| EBITDA | -$26,944 | -$27,506 | -$27,418 | -$13,865 |
| % Margin | – | – | – | – |